TY - JOUR T1 -新冠肺炎轻症患者早期使用硝唑胺:随机、安慰剂对照试验JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.03725 -2020欧元SP - 2003725 AU -罗科,帕特里夏·r·m . AU -席尔瓦,佩德罗·l . AU -克鲁兹,费尔南达f . AU -初级,马可·安东尼奥·c·m . Tierno盟——保罗·g·m·m . AU -莫拉,马科斯a . AU - De Oliveira Luis Frederico g . AU -利马Ezequiel a c c . AU -多斯桑托斯,非盟-初级,沃尔特·f . AU -费尔南德斯,安娜葆拉·s . m . AU - Franchini Kleber g . AU - Magri埃里克AU -德·莫拉埃斯,奈良f . AU - Goncalves,何塞马里奥•j . AU - Carbonieri梅勒妮n . AU -多斯桑托斯Ivonise s . AU - Paes纳塔莉亚f . AU -马舍尔,葆拉·v . m . AU -罗查,Raissa卡瓦略·p . AU -Alex F. AU - Alves, Pedro Augusto AU - Modena, José Luiz P. AU - Cordeiro, Artur T. AU - Trivella, Daniela B. B. AU - Marques, Rafael e . AU - Luiz, Ronir R. AU - Pelosi, Paolo AU - Lapa e - Silva, Jose Roberto A2 -N2 - Nitazoxanide在体外具有广谱抗病毒活性。然而，没有证据表明它对SARS-CoV-2感染有影响。在一项多中心、随机、双盲、安慰剂对照试验中，纳入了在出现Covid-19症状(干咳、发烧和/或疲劳)3天后出现的成年患者。鼻咽拭子经RT-PCR确认SARS-CoV2感染后，患者按1:1随机接受硝唑胺(500 mg)或安慰剂，TID，持续5天。主要结果是症状完全消除。次要结果是病毒载量、实验室检查、血清炎症标志物和住院率。 Adverse events were also assessed.From June 8 to August 20, 2020, 1575 patients were screened. Of these, 392 (198 placebo, 194 nitazoxanide) were analysed. Median time from symptom onset to first dose of study drug was 5 (4–5) days. At the 5-day study visit, symptom resolution did not differ between the nitazoxanide and placebo arms. Swabs collected were negative for SARS-CoV-2 in 29.9% of patients in the nitazoxanide arm versus 18.2% in the placebo arm (p=0.009). Viral load was also reduced after nitazoxanide compared to placebo (p=0.006). The percent viral load reduction from onset to end of therapy was higher with nitazoxanide (55%) than placebo (45%) (p=0.013). Other secondary outcomes were not significantly different. No serious adverse events were observed.In patients with mild Covid-19, symptom resolution did not differ between nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly.This was the first study to evaluate the effect of early nitazoxanide therapy in mild Covid-19. Nitazoxanide did not accelerate symptom resolution after 5 days of therapy but did reduce viral load significantly with no serious adverse events. ER -